[Pathophysiology and treatment of renal osteodystrophy].
D000535:Aluminum / Q000009:adverse effects; D000818:Animals; D002112:Calcifediol / Q000378:metabolism; D002116:Calcitonin / Q000502:physiology; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D003131:Combined Modality Therapy / Q000379:methods; D004285:Dogs; D006493:Heparin / Q000009:adverse effects; D006706:Homeostasis; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000503:physiopathology / Q000628:therapy; D007668:Kidney / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D010018:Osteomalacia / Q000209:etiology / Q000503:physiopathology; D010280:Parathyroid Glands / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000378:metabolism; D051381:Rats; D006435:Renal Dialysis; D014511:Uremia / Q000150:complications
D010281:Parathyroid Hormone; D006493:Heparin; D002116:Calcitonin; D000535:Aluminum; D002112:Calcifediol
Patofiziologiia i lechenie na renalnata osteodistrofiia.